XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Clinical trial NCT05275374 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05275374
Sponsor: Xynomic Pharmaceuticals, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer BRAF V600 Mutation Melanoma Colorectal Cancer Thyroid Cancer Nonsmall Cell Lung Cancer

Start date: 2025-12-31
Primary completion: 2027-12-30
Enrollment: 221

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.